CD8A and cancer: In the model reported by Wilson et al., using data from a TC1 murine tumor model, the authors considered two types of interactions between tumor cells and T cells: (1) the interaction with Treg through TGF-β release to investigate the anti-TGF-β treatment, and (2) the interaction with CD8+ cells, by using cancer vaccines as effector cell stimulators [30].